- Home
- NMAI vs FDMT Comparison
NMAI vs FDMT Comparison
Compare NMAI & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMAI
- FDMT
- Stock Information
- Founded
- NMAI 2021
- FDMT 2013
- Country
- NMAI United States
- FDMT United States
- Employees
- NMAI N/A
- FDMT N/A
- Industry
- NMAI Investment Managers
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- NMAI Finance
- FDMT Health Care
- Exchange
- NMAI Nasdaq
- FDMT Nasdaq
- Market Cap
- NMAI 429.9M
- FDMT 391.8M
- IPO Year
- NMAI N/A
- FDMT 2020
- Fundamental
- Price
- NMAI $12.93
- FDMT $10.61
- Analyst Decision
- NMAI
- FDMT Strong Buy
- Analyst Count
- NMAI 0
- FDMT 8
- Target Price
- NMAI N/A
- FDMT $30.63
- AVG Volume (30 Days)
- NMAI 74.8K
- FDMT 775.9K
- Earning Date
- NMAI 01-01-0001
- FDMT 11-12-2025
- Dividend Yield
- NMAI 13.14%
- FDMT N/A
- EPS Growth
- NMAI N/A
- FDMT N/A
- EPS
- NMAI 0.64
- FDMT N/A
- Revenue
- NMAI N/A
- FDMT $33,000.00
- Revenue This Year
- NMAI N/A
- FDMT $9,656.76
- Revenue Next Year
- NMAI N/A
- FDMT N/A
- P/E Ratio
- NMAI $19.03
- FDMT N/A
- Revenue Growth
- NMAI N/A
- FDMT N/A
- 52 Week Low
- NMAI $10.60
- FDMT $2.24
- 52 Week High
- NMAI $12.55
- FDMT $10.26
- Technical
- Relative Strength Index (RSI)
- NMAI 48.23
- FDMT 74.15
- Support Level
- NMAI $12.90
- FDMT $8.50
- Resistance Level
- NMAI $13.25
- FDMT $10.03
- Average True Range (ATR)
- NMAI 0.14
- FDMT 0.65
- MACD
- NMAI -0.02
- FDMT 0.11
- Stochastic Oscillator
- NMAI 35.12
- FDMT 95.42
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.